Back to top
more

Castle Biosciences (CSTL)

(Delayed Data from NSDQ)

$20.34 USD

20.34
112,239

+0.83 (4.25%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $20.38 +0.04 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CSTL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Castle Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 243 259 330 410 99
Receivables 38 23 17 13 15
Notes Receivable 0 0 0 0 0
Inventories 8 4 2 2 1
Other Current Assets 6 6 5 5 2
Total Current Assets 296 292 354 430 117
Net Property & Equipment 25 14 10 7 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 1 1 1 1 1
Deferred Charges 0 0 0 0 0
Intangibles 117 126 89 0 0
Deposits & Other Assets 1 1 2 2 0
Total Assets 453 447 463 439 120
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 10 5 3 2 2
Current Portion Long-Term Debt 0 0 0 0 6
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 36 30 21 12 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 7 0
Total Current Liabilities 48 36 25 21 15
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 1 1 1 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 19
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 18 2 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 62 48 51 24 35
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 609 560 505 478 137
Retained Earnings -218 -161 -94 -63 -52
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 391 399 412 416 85
Total Liabilities & Shareholder's Equity 453 447 463 439 120
Total Common Equity 391 399 412 416 85
Shares Outstanding 26.90 26.30 25.30 20.10 17.00
Book Value Per Share 14.55 15.18 16.27 20.68 5.01

Fiscal Year End for Castle Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 243 230 226 232
Receivables NA 38 37 31 28
Notes Receivable NA 0 0 0 0
Inventories NA 8 6 6 5
Other Current Assets NA 6 7 6 7
Total Current Assets NA 296 280 269 271
Net Property & Equipment NA 25 22 21 18
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 1 1 1 1
Deferred Charges NA 0 0 0 0
Intangibles NA 117 120 122 124
Deposits & Other Assets NA 1 2 1 1
Total Assets NA 453 436 425 427
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 10 7 7 10
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 36 28 25 18
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 48 36 34 30
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 62 50 47 42
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 609 602 588 575
Retained Earnings NA -218 -216 -209 -190
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 391 386 379 385
Total Liabilities & Shareholder's Equity NA 453 436 425 427
Total Common Equity 0 391 386 379 385
Shares Outstanding 27.40 26.90 26.90 26.80 26.60
Book Value Per Share 0.00 14.55 14.34 14.13 14.48